#interferon

People of European or African ancestry who were hospitalized for COVID-19 are more likely to carry particular genetic variants.

Screening patients for autoantibodies against interferons could help predict which patients are more likely to become very sick.

Large European study finds that more than 1 in 10 people with HIV acquire HCV again.

Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.

Apparently, the virus inhibits natural antiviral effects, the body’s first line of defense, and manipulates them to persist indefinitely.

A study of Swiss individuals coinfected with hepatitis C vand HIV found that, during the era of interferon HCV treatment, the population had a...

The real-world cure rates offered by Sovaldi (sofosbuvir)-based hep C virus regimens have not been as good as those seen in clinical trials

With the FDA approval of Sovaldi (sofosbuvir) and Olysio (simeprevir), many people with hepatitis C, including those coinfected with HIV...

The FDA has approved Sovaldi (sofosbuvir), a once-daily oral nucleotide analog polymerase inhibitor to treat people with hepatitis C.

Researchers reveled in promising new data on forthcoming hepatitis C therapies.

Vertex Pharmaceuticals’ hepatitis C antiviral Incivek (telaprevir) has caused a number of deaths due to serious skin reactions.

People living with hepatitis C virus (HCV) and who have high blood pressure should see an eye specialist while undergoing therapy with pegylat...

For people living with both HIV and hepatitis C virus (HCV), not only does curative hepatitis C treatment reduce the risk of liver-related dis...

Monitoring people undergoing therapy for hepatitis C virus (HCV) infection for depression, and taking steps to manage this common side effect...

Adding BMS-790052, an experimental hepatitis C drug being developed by Bristol-Myers Squibb, to pegylated interferon and ribavirin...

Coffee consumption slows liver disease progression and increase the chances of success while undergoing treatment for chronic hepatitis C.